- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02130648
Non Ivasive Prenatal Diagnosis (NIPD) of Cystic Fibrosis
Non-invasive Prenatal Diagnosis (NIPD) of Cystic Fibrosis by Quantitative Real Time MEMO-PCR
Study Overview
Status
Intervention / Treatment
Detailed Description
The recent development of techniques to analyze foetal DNA circulating in blood maternal opened new perspectives for prenatal diagnosis (PD). Non-invasive PND (NIPD) is now the method of choice for the determination of fetal sex (genetic disorders linked to X chromosome) and rhesus genotype. NIPD begins to find applications in the diagnosis of monogenic diseases for mutations of paternal transmission. However a number of technical challenges still hamper diagnostic applications in routine, and have to be resolved taking into account the aspects of cost, reliability (false negative ..) and complexity of equipment and bioinformatics studies.
The investigators propose to develop and validate an analytical and clinical NIPD test for cystic fibrosis from maternal blood by analysis circulating free fetal DNA (cff-DNA), searching for the paternal mutation in families with CFTR compound heterozygosity.
The test method based on MEMO associated with a platform for real-time PCR can be used for the detection of trace DNA mutant. This technique is commonly used for mutations in mosaic (less than 1%) of genes common cancers. Positive detection of the paternal mutation is always checked by a second mini-sequencing technique.
Prior to any specific CFTR test, the DNA profile of each sample will be determined using a commercial kit of Mini STR adapted to study casework. A tri-allelic profile for markers will prove the presence of fetal DNA in the studied specimen and will thus limit false negatives associated with the lack or insufficient amounts of cff-DNA.
The validation step of the investigators analytical methods will be made on chimeric DNA control samples artificially created. Then the test will be clinicaly validated by a retrospective study of maternal serum from pregnant women, who have been the subject of PND or PGD (preimplantation genetic diagnosis) of CF request in the laboratory during the study period (2012 to 2013).
The investigators structure is a reference center for PGD, PND and NBS (newborn screening) of cystic fibrosis. The samples will be collected in accordance with current regulations.The pre-analytical sample treatment will be done in real time and plasma will be stored for the second step of the study.
The validation of the proposed tests will permit :
- To have an external quality control (QC) confirming the presence of a minor DNA in the studied sample. This QC could be used for all NIPD tests based on the search of a genomic sequence absent from the maternal genome
- To have a highly sensitive method to detect trace mutant DNA which can be develop for new NIPD tests in other monogenic diseases by detecting mutations of the same nature.
The investigators project, limited to the search for the paternal allele in the family with CFTR compound heterozygosity, is a first step in the implementation of a prenatal diagnosis approach of cystic fibrosis that the investigators aim to develop in order to to reduce invasive procedures.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Anne VECHERE
- Phone Number: 33467330812
- Email: a-verchere@chu-montpellier.fr
Study Contact Backup
- Name: Sandrine BARBAS
- Phone Number: 33467330813
- Email: s-barbas@chu-montpellier.fr
Study Locations
-
-
-
Montpellier, France, 34295
- Recruiting
- Centre Hospitalier Universitaire de Montpellier
-
Contact:
- Sandrine BARBAS
- Phone Number: 33467330813
- Email: s-barbas@chu-montpellier.fr
-
Contact:
- Anne VERCHERE
- Phone Number: 33467330812
- Email: a-verchere@chu-montpellier.fr
-
Principal Investigator:
- Mireille CLAUSTRES
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria:
- pregnant women with a risk of cystic fibrosis for the foetus
Exclusion criteria:
- both parents have the same CF mutant allele
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Prenatal diagnosis
Prenatal diagnosis witch A sampling of blood de 14 ml
|
A sampling of blood de 14 ml
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Analysis circulating free fetal DNA
Time Frame: 10th week with regard to the term of the pregnancy
|
Analytical and clinical NIPD test for cystic fibrosis from maternal blood by analysis circulating free fetal DNA (cff-DNA), searching for the paternal mutation in families with CFTR compound heterozygosity. The test method based on MEMO associated with a platform for real-time PCR can be used for the detection of trace DNA mutant. |
10th week with regard to the term of the pregnancy
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mireille CLAUSTRES, Laboratoire de Genetique Moleculaire Institut de Recherche Clinique INSERM 827 640, avenue du Doyen giraud 34295 MONTPELLIER cedex 5
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Infant, Newborn, Diseases
- Genetic Diseases, Inborn
- Pancreatic Diseases
- Neoplasms, Cystic, Mucinous, and Serous
- Fibrosis
- Cystic Fibrosis
- Cystadenocarcinoma
- Cystadenocarcinoma, Mucinous
Other Study ID Numbers
- UF9039
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Noninvasive Mucinous Cystadenocarcinoma of Ovary
-
Lawson Health Research InstituteUniversity of Western Ontario, CanadaTerminatedMucinous Cystic Tumor With Moderate Dysplasia | Mucinous Cystadenoma of Pancreas | Mucinous Cystadenocarcinoma of Pancreas | Benign Neoplasm of PancreasCanada
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)TerminatedOvarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Primary Peritoneal Carcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Mucinous Cystadenocarcinoma | Undifferentiated Ovarian Carcinoma | Stage III Ovarian CancerUnited States
-
Abramson Cancer Center of the University of PennsylvaniaTerminatedMucinous Adenocarcinoma of the Rectum | Mucinous Adenocarcinoma of the ColonUnited States
-
Zhejiang Cancer HospitalUnknown
-
University of WashingtonNational Cancer Institute (NCI)CompletedFallopian Tube Cancer | Peritoneal Cavity Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian Mucinous Cystadenocarcinoma and other conditionsUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnMucinous Adenocarcinoma of the Rectum | Signet Ring Adenocarcinoma of the Rectum | Mucinous Adenocarcinoma of the Colon | Signet Ring Adenocarcinoma of the Colon | Stage I Colon Cancer | Stage I Rectal Cancer
-
Mucpharm Pty LtdWake Forest University Health Sciences; Catharina Ziekenhuis Eindhoven; Hospital... and other collaboratorsNot yet recruitingPseudomyxoma Peritonei | Peritoneal Cancer | Mucinous Adenocarcinoma | Mucinous Tumor
-
National Cancer Institute (NCI)CompletedOvarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Brenner Tumor | Stage III Ovarian Epithelial Cancer | Ovarian Mucinous Cystadenocarcinoma | Ovarian Mixed Epithelial Carcinoma | Ovarian Undifferentiated...United States
-
John HaysSanofiUnknownMucinous Adenocarcinoma of the Rectum | Signet Ring Adenocarcinoma of the Rectum | Mucinous Adenocarcinoma of the Colon | Signet Ring Adenocarcinoma of the Colon | Stage IV Colon Cancer | Stage IV Rectal CancerUnited States
-
National Cancer Institute (NCI)CompletedFallopian Tube Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Brenner Tumor | Stage III Ovarian Epithelial Cancer | Ovarian Mucinous Cystadenocarcinoma | Ovarian Undifferentiated AdenocarcinomaUnited States
Clinical Trials on A sampling of blood
-
Institute of Tropical Medicine, BelgiumSRI International; Sihanouk Hospital Center of HOPECompletedSystemic Inflammatory Response Syndrome | Melioidosis | Suspected or Confirmed Bloodstream InfectionsCambodia
-
University Hospital, MontpellierRecruiting
-
University Hospital, BordeauxRegional Health Agency New AquitaineCompletedPoisoning by Psychoactive SubstancesFrance
-
Medical University of GrazJoanneum Research Forschungsgesellschaft mbHCompleted
-
CardioRenalCompletedPotassium MeasurementBelgium
-
Nantes University HospitalCR2TI, INSERM, UMR1064RecruitingBipolar Disorder I | Bipolar Disorder II | Schizoaffective Disorder, Depressive TypeFrance
-
Centre Hospitalier Universitaire DijonCompleted
-
Assistance Publique Hopitaux De MarseilleCompletedChronic Renal InsufficiencyFrance
-
Centre Hospitalier Universitaire DijonCompletedPatients With Intellectual Disabilities Without an Obvious Clinical Diagnosis | Patients With Normal Array CGH and Previous Negative Genetic Investigations (WES-solo or WES-trio)France
-
Centre Hospitalier Universitaire DijonCompletedPatients With Periodontal DiseaseFrance